Exclusive-US FDA cleared pricey rare disease drug over reviewer objections

The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...
InvestorsHub on MSN

Evotec Shares Drop Over 9% as Weakness in Drug Discovery Drags Nine-Month Results

Evotec SE (NASDAQ:EVO) shares plunged 9.3% in premarket trading Wednesday after the German biotech firm reported a decline in ...